All In Biotech

Drug Trial Radar · NCT06725524

A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma

A Phase 1, Open-Label, Multi-center Study Evaluating the Safety and Tolerability of of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Oct 12, 2021

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Dec 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, multi-center study to evaluate the safety of JMT601 in the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma and to determine the recommended dose for Phase 2 studies (RP2D). Study consists of 2 parts. The first part is a dose-escalation part using a 3+3 design with up to 6 dose(0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 12 mg/kg and 20 mg/kg) escalation cohorts at increasing levels. The second part is a dose-expansion part at R2PD dose to assess preliminary efficacy of JMT601.

Conditions

  • B-cell Non Hodgkin Lymphoma

Interventions

  • JMT601Biological

    intravenous infusion on day 1 once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT) and maximum tolerated dose(MTD)Time frame: DLTs and MTD: Up to 28 days after the first dose
  2. Incidence of treatment-emergent adverse events (TEAEs)Time frame: TEAEs: Up to 90 days after last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.